Draft:Adagio Therapeutics
| Company type | Public |
|---|---|
| Nasdaq: ADGI | |
| Founded | June 2020 |
| Founder |
|
| Headquarters | , United States |
Key people |
|
| Revenue | -US$227 million (2021)[3] |
Number of employees |
Adagio Therapeutics is a clinical stage biopharmaceutical company focused on development of antibody-based treatments for infectious disease.[3] The company was founded in mid-2020 by Tillman Gerngross, Laura Walker and René Russo.[1][5] In 2021, the company had an injectable treatment for COVID-19, going by the working name ADG20[6] and generic name adintrevimab,[2] which was thought to potentially be effective against multiple variants due to its being targeted to a spike protein antigen apparently conserved across multiple coronaviruses, a discovery made by Walker.[1][7] Particular interest emerged from evidence that ADG20 was effective against the Omicron variant; however, prediction that the conserved epitope target would lead to equivalent efficacy across variants turned out to be incorrect and the therapeutic showed drastically reduced efficacy against Omicron vs earlier variants.[2][8]
The marketing position of the therapeutic is as a supplementary treatment to current treatment options.[1] Further, the firm is one of several developing monoclonal antibody treatments for COVID-19,[1] though its approach of seeking a single treatment targeting the SARSr-CoV virus species has been touted as setting it apart from competitors.[4] The adintrevimab therapeutic is also distinguished from other similar anti-viral treatments by being administered intramuscularly rather than intravenously.[2]
As of 2022 the company was unusual for a "loss-making biotech" in having no debt, relying rather solely off of shareholder funding.[3]
Adagio was a spin out from the Lebanon, New Hampshire-based Adimab.[1][9] It went public in August 2021.[1] Co-founder and CEO Gerngross announced his resignation in February 2022.[2]
Notable affiliated people[edit]
- Terry McGuire, member of the Board
Publications[edit]
These are peer-reviewed publications where an author was an Adagio employee and noted as such in the author affiliations.
- Walker LM (corresponding author): Kaku CI, Champney ER, Normark J, Garcia M, Johnson CE, Ahlm C, Christ W, Sakharkar M, Ackerman ME, Klinström J, Forsell MN, Walker LM. "Broad anti-SARS-CoV-2 antibody immunity induced by heterologous ChAdOx1/mRNA-1273 vaccination". Science. 375 (6584): 1041–1047 – via Internet Archive.
References[edit]
- ^ a b c d e f g h Gardizy, Anissa (7 December 2021). "In the long war against COVID, this Waltham biotech is designing a way to fight all variants". The Boston Globe. Retrieved 1 August 2023. Note: only the first three paragraphs are accessible to people without a subscription.
- ^ a b c d e Gardizy, Anissa (31 March 2022). "Adagio wants FDA OK on virus antibody". Business. The Boston Globe. pp. D2. Retrieved 4 August 2023 – via Newspapers.com (Wikipedia Library).
- ^ a b c "When Will Adagio Therapeutics, Inc. (NASDAQ:ADGI) Breakeven?". Simply Wall St. Yahoo! Finance. 7 April 2022. Retrieved 3 August 2023.
- ^ a b Lippman, John (30 August 2020). "New Line of Attack". Business & Money. Valley News. Vol. 69, no. 83. pp. B1, 2. Retrieved 4 August 2023 – via Newspapers.com (Wikipedia Library). — URL for page B2
- ^ Gardizy, Anissa (8 December 2021). "A different weapon in the war on COVID". The Boston Globe. Vol. 300, no. 161. pp. A1, A8. Retrieved 4 August 2023 – via Newspapers.com (Wikipedia Library). —
- ^ "Adagio Therapeutics initiated with a Buy at Stifel". The Fly. 31 August 2021. Retrieved 1 August 2023 – via Gale General OneFile (Wikipedia Library).
- ^ "Adagio Therapeutics initiated with a Buy at Jefferies". The Fly. New Jersey, United States. 31 August 2021. Retrieved 1 August 2023 – via Gale General OneFile (Wikipedia Library).
- ^ Gatlin, Allison (16 December 2021). "Adagio Therapeutics Continues Its Wild Ride — How Two Tests Led To A Triple-Digit Gain". Technology. Investor's Business Daily. Retrieved 3 August 2023.
- ^ "Adimab Spins Out Adagio Therapeutics to Develop Broadly Protective Coronavirus Antibodies" (Press release). Adimab. 16 July 2020. Retrieved 3 August 2023.